by Madaline Spencer | Feb 13, 2025
Deeksha Vishwamitra, Janssen Research & Development, discusses an analysis of the TRIMM-2 clinical trial evaluating combination therapy tal-DP in patients with multiple myeloma. Multiple myeloma is a bone marrow-based plasma cell neoplasm...
by Madaline Spencer | Feb 12, 2025
Anita D’Souza, MD, Medical College of Wisconsin, discusses results from the MajesTEC-2 and TRIMM-2 clinical trials for combination therapy teclistamab + daratumumab + pomalidomide (tec-DP) in patients with multiple myeloma. Multiple myeloma is a bone...
by Madaline Spencer | Feb 11, 2025
Arturo Molina, MD, Protagonist Therapeutics, discusses results from the phase 2 REVIVE clinical trial testing rusfertide in patients with polycythemia vera (PV). PV is a myeloproliferative disorder characterized by an elevated absolute red blood cell...
by Madaline Spencer | Feb 5, 2025
Emma Searle, PhD, The Christie NHS Foundation Trust and University of Manchester, discusses bleximenib in combination with chemotherapy to treat patients with acute myeloid leukemia (AML). AML is a group of neoplasms arising from precursor cells...
by Madaline Spencer | Feb 4, 2025
Carolina Schinke, MD, University of Arkansas for Medical Sciences, discusses differences in clinical outcomes of black patients with multiple myeloma treated with talquetamab. Multiple myeloma is a bone marrow-based plasma cell neoplasm characterized by...
